Fresenius Medical Care Rises On Unusually High Volume (FMS)

NEW YORK ( TheStreet) -- Fresenius Medical Care Corporation (NYSE: FMS) is trading at unusually high volume Tuesday with 715,461 shares changing hands. It is currently at 6.7 times its average daily volume and trading up $1.77 (+2.6%) at $68.45 as of 12:40 p.m. ET.

Fresenius Medical Care has a market cap of $21.06 billion and is part of the health care sector and health services industry. Shares are down 1.9% year to date as of the close of trading on Monday.

Fresenius Medical Care AG & Co. KGaA, a kidney dialysis company, provides products and services for the treatment of end-stage renal disease worldwide. The company owns and operates dialysis clinics that provide dialysis treatment, and related laboratory and diagnostic services. The company has a P/E ratio of 19.1, below the average health services industry P/E ratio of 20.7 and above the S&P 500 P/E ratio of 17.7.

TheStreet Ratings rates Fresenius Medical Care as a buy. The company's strengths can be seen in multiple areas, such as its growth in earnings per share, revenue growth, expanding profit margins, good cash flow from operations and largely solid financial position with reasonable debt levels by most measures. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. You can view the full Fresenius Medical Care Ratings Report.

See all heavy volume stocks in our stocks moving on unusual volume list or get investment ideas from our investment research center.

Interested in other stocks that are rising on unusually high volume? Get free SMS text alerts sent to you when the action happens by texting HVUP to 95370 or select from multiple alert options.
null

If you liked this article you might like

Mining and Resources Lead Europe's Benchmarks Lower

European Stocks Diverge as Investors Weigh Economic Optimism With Mixed Earnings

Wednesday's Earnings Push Stocks Lower as Mood Sours in Europe

Here's What's Boosting European Benchmarks

Drug Price Inflation and a Patent Cliff Could Trigger a Wave of Deals in Generic Drugs Space